UCB (UCBJY) Net Income (Discontinued Operations) : $0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is UCB Net Income (Discontinued Operations)?

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods. UCB's Net Income (Discontinued Operations) for the six months ended in Dec. 2023 was $0 Mil. Its Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was $0 Mil.

UCB Net Income (Discontinued Operations) Historical Data

The historical data trend for UCB's Net Income (Discontinued Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Net Income (Discontinued Operations) Chart

UCB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Discontinued Operations)

Get a 7-Day Free Trial

2.22

3.39

-2.12

UCB Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income (Discontinued Operations)	Get a 7-Day Free Trial															-1.13	-	-2.12	-	-

UCB Net Income (Discontinued Operations) Calculation

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods.

Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0 Mil.

UCB Net Income (Discontinued Operations) Related Terms

Thank you for viewing the detailed overview of UCB's Net Income (Discontinued Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB (UCBJY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (OTCPK:UCBJY) » Definitions » Net Income (Discontinued Operations)

Comparable Companies

Traded in Other Exchanges

UCBJF:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Belgium UCB:Austria

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).